Kirillov V I, Zernov N G, Arion V Ia, Tebloeva L T, Riabchikov O P
Urol Nefrol (Mosk). 1989 Sep-Oct(5):17-21.
A total of 40 children who suffered from acute or chronic pyelonephritis underwent immunological treatment with polypeptide drug tactivin. There was an evidence of clinical and laboratory improvement in 82.5 per cent of treated persons, first manifest in decreased proteinuria and normalized urinary sedimentation, and then in lower levels of bacteriuria due to the developing resistance to infectious agents. In 15 per cent of tactivin-treated children leukocyturia persisted though the disease progression was hindered. In the course of the treatment no side-effects were noted. In line with the stimulation of humoral immune response and activation of the complement system, tactivin administration evoked the competence of T-lymphocytes and potentiated the development of this link of immune system. As part of combined treatment the above preparation favourably affected the disease pathogenesis in children.
共有40名患有急性或慢性肾盂肾炎的儿童接受了多肽药物tactivin的免疫治疗。82.5%的接受治疗者有临床和实验室改善的迹象，首先表现为蛋白尿减少和尿沉渣正常化，然后由于对感染因子产生耐药性，菌尿水平降低。在接受tactivin治疗的儿童中，15%的人虽然疾病进展受到阻碍，但白细胞尿持续存在。在治疗过程中未观察到副作用。随着体液免疫反应的刺激和补体系统的激活，tactivin的给药增强了T淋巴细胞的活性，并促进了免疫系统这一环节的发展。作为联合治疗的一部分，上述制剂对儿童疾病的发病机制产生了有利影响。
